0001711754
false
0001711754
2023-08-16
2023-08-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 16, 2023
| INMUNE BIO INC. |
| (Exact name of registrant as specified in charter) |
| Nevada |
|
001-38793 |
|
47-5205835 |
| (State or other jurisdiction |
|
(Commission File Number) | |
(IRS Employer |
| of incorporation) |
|
|
|
Identification No.) |
225 NE Mizner Bl vd., Suite 640, Boca Raton,
Florida 334327
(Address of Principal Executive Offices) (Zip Code)
(858) 964 3720
(Registrant’s Telephone Number, Including
Area Code)
Not Applicable
(Former Name or Former Address, If Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mart if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, par value $0.001 per share |
|
INMB |
|
The NASDAQ Stock Market LLC |
Item 1.01. Entry into a Material Definitive Agreement.
As previously reported on a Current Report on Form 8-K, on March 10,
2021, INmune Bio Inc. (the “Company”), entered into an At-The-Market Sales Agreement (the “Sales Agreement”) with
BTIG, LLC (“BTIG”), pursuant to which the Company may offer and sell, from time to time, through BTIG, as sales agent, shares
of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $45,000,000,
subject to certain limitations on the amount of Common Stock that may be offered and sold by the Company set forth in the Sales Agreement.
The Company is not obligated to make any sales of Common Stock under the Sales Agreement and any determination by the Company to do so
will be dependent, among other things, on market conditions and the Company’s capital raising needs.
On August 16, 2023, the Company and BTIG entered into Amendment No.
1 to the Sales Agreement (“Amendment No. 1 to the Sales Agreement”) in order to provide that the offers and sales of Common
Stock by the Company under the Sales Agreement, as amended, if any, will be made through a prospectus supplement to the prospectus forming
a part of the Company’s shelf registration statement on Form S-3 (File No. 333-254221) declared effective by the Securities
and Exchange Commission (the “SEC”) on May 5, 2021 (the “Registration Statement”). The Company filed with the
SEC a prospectus supplement dated August 16, 2023, specifically relating to offers and sales of Common Stock under the Sales Agreement
(the “ATM Prospectus Supplement”), together with the prospectus forming a part of the effective registration statement.
Shares may be sold through the ATM Prospectus Supplement by any method
deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, including
sales made through The Nasdaq Capital Market or any other trading market for the common stock, sales made to or through a market maker
other than on an exchange or through an electronic communications network, or in negotiated transactions pursuant to terms set forth in
a placement notice delivered by the Company to BTIG under the Sales Agreement. Upon delivery of a placement notice and subject to the
terms and conditions of the Sales Agreement, BTIG will use commercially reasonable efforts, consistent with its normal trading and sales
practices, applicable state and federal law, rules and regulations, and the rules of The Nasdaq Capital Market, to sell the Shares from
time to time based upon the Company’s instructions, including any price, time or size limits specified by the Company. BTIG is not
obligated to purchase any shares of Common Stock on a principal basis pursuant to the Sales Agreement.
The foregoing description of Amendment No. 1 to the Sales Agreement
does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment No. 1 to the Sales Agreement.
A copy of the Amendment No. 1 to the Sales Agreement is filed with this Current Report on Form 8-K as Exhibit 1.1 and is incorporated herein by reference.
A copy of the opinion of Sichenzia Ross Ference LLP relating to the
validity of the Shares that may be offered and sold under the ATM Prospectus Supplement, is filed with this Current Report on Form 8-K
as Exhibit 5.1.
This Current Report on Form 8-K does not constitute an offer to
sell or the solicitation of offers to buy any securities of the Company, and shall not constitute an offer, solicitation or sale of any
security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction.
Item 9.01 Financial statements and Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 16, 2023 |
INMUNE BIO INC. |
| |
|
| |
By: |
/s/
David Moss |
| |
|
David Moss |
| |
|
Chief Financial Officer |
3
Exhibit 1.1
INMUNE
BIO Inc.
AMENDMENT
NO. 1 TO
At-the-market
SALES AGREEMENT
August 16, 2023
BTIG, LLC
65 East 55th Street
New York, NY 10022
Ladies and Gentlemen:
Reference is made to the At-The-Market
Sales Agreement, dated March 10, 2021, including the Schedules and Exhibits thereto (the “Sales Agreement”),
between INmune Bio Inc., a Nevada corporation (the “Company”), and BTIG, LLC (“BTIG”
and, together with the Company, the “Parties”), pursuant to which the Company agreed that it may issue and sell
to or through BTIG, as sales agent and/or principal, up to that number of shares of the Company’s common stock, par value $0.001
per share, having an aggregate offering price of $45,000,000, subject to the limitations set forth in Section 5(c) of the Sales
Agreement.
The Parties wish to modify
and amend the Sales Agreement as provided in this Amendment No. 1, dated August 16, 2023, to the Sales Agreement (this “Amendment”).
All capitalized terms used in this Amendment and not otherwise defined herein shall have the respective meanings assigned to such terms
in the Sales Agreement.
BTIG and the Company hereby
agree as follows:
A. Amendments to Sales
Agreement. The Sales Agreement is hereby amended, effective August 16, 2023, as follows:
1. The second paragraph
of Section 1 of the Sales Agreement is hereby deleted in its entirety and replaced with the following:
“The Company
has filed, in accordance with the provisions of the Securities Act of 1933, as amended, and the rules and regulations thereunder (collectively,
the “Securities Act”), with the Commission, not earlier than three years prior to the date hereof, a shelf registration
statement on Form S-3 (File No. 333-254221), including a base prospectus, relating to certain securities, including the Common Stock,
to be issued from time to time by the Company, and which incorporates by reference documents that the Company has filed or will file in
accordance with the provisions of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (collectively,
the “Exchange Act”). The Company has prepared a prospectus supplement to the base prospectus included as part
of such registration statement at the time it became effective specifically relating to the offering of Common Stock pursuant to this
Agreement (the “Prospectus Supplement”). The Company will furnish to BTIG, for use by BTIG, copies of the prospectus
included as part of such registration statement at the time it became effective, as supplemented by the Prospectus Supplement, relating
to the offering of Common Stock pursuant to this Agreement. Except where the context otherwise requires, “Registration Statement,”
as used herein, means such registration statement, as amended at the time of such registration statement’s effectiveness for purposes
of Section 11 of the Securities Act, as well as any new registration statement as may have been filed pursuant to Section 7(aa),
including (1) all documents filed as a part thereof or incorporated or deemed to be incorporated by reference therein, (2) any information
contained or incorporated by reference in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b)
under the Securities Act, to the extent such information is deemed, pursuant to Rule 430B under the Securities Act, to be part of
the registration statement at the effective time, and (3) any abbreviated registration statement filed pursuant to Rule 462(b) under
the Securities Act to register the offer and sale of additional shares of Common Stock pursuant to this Agreement. Except where the context
otherwise requires, “Prospectus,” as used herein, means the base prospectus included in the registration statement
at the time it became effective, including all documents incorporated therein by reference to the extent such information has not been
superseded or modified in accordance with Rule 412 under the Securities Act (as qualified by Rule 430B(g) under the Securities
Act), as it may be supplemented by the Prospectus Supplement, in the form in which such prospectus and/or Prospectus Supplement have most
recently been filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act, together with any “issuer
free writing prospectus,” as defined in Rule 433 of the Securities Act (“Rule 433”), relating
to the Common Stock that (i) is required to be filed with the Commission by the Company or (ii) is exempt from filing pursuant
to Rule 433(d)(5)(i), in each case in the form filed or required to be filed with the Commission or, if not required to be filed,
in the form retained in the Company’s records pursuant to Rule 433(g). Any reference herein to the Registration Statement,
the Prospectus or any amendment or supplement thereto shall be deemed to refer to and include the documents incorporated by reference
therein, and any reference herein to the terms “amend,” “amendment” or “supplement” with respect to
the Registration Statement or the Prospectus shall be deemed to refer to and include the filing after the execution hereof of any document
with the Commission deemed to be incorporated by reference therein (the “Incorporated Documents”). For purposes
of this Agreement, all references to the Registration Statement, the Prospectus or to any amendment or supplement thereto shall be deemed
to include any copy filed with the Commission pursuant to either the Electronic Data Gathering Analysis and Retrieval System, or if applicable,
the Interactive Data Electronic Applications (collectively “EDGAR”).
2. Section 6(a)
of the Sales Agreement is hereby deleted in its entirety and replaced with the following:
“Registration
Statement and Prospectus. The Registration Statement was declared effective under the Securities Act by the Commission on May 5, 2021,
and any post-effective amendment thereto and any Rule 462(b) Registration Statement have also been declared effective by the Commission
or became effective upon filing under the Securities Act. The Company has not received from the Commission any notice pursuant to Rule 401(g)(1)
under the Securities Act objecting to the use of the shelf registration statement form. At the time of the initial filing of the Registration
Statement, the Company paid the required Commission filing fees relating to the Shares in accordance with Rules 456(a) and 457(o)
under the Securities Act. The Company has complied to the Commission’s satisfaction with all requests of the Commission for additional
or supplemental information. No stop order suspending the effectiveness of the Registration Statement or any Rule 462(b) Registration
Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the best knowledge of the Company,
are contemplated or threatened by the Commission. At the time of (i) the initial filing of the Registration Statement with the Commission
and (ii) the most recent amendment thereto for the purposes of complying with Section 10(a)(3) of the Securities Act (whether such amendment
was by post-effective amendment, incorporated report filed pursuant to Section 13 or 15(d) of the Exchange Act or form of prospectus),
the Company met the then applicable requirements for use of Form S-3 under the Securities Act. The Registration Statement and the offer
and sale of the Shares as contemplated hereby meet the requirements of Rule 415 under the Securities Act and comply in all material
respects with said Rule. In the section entitled “Plan of Distribution” in the Prospectus Supplement, the Company has named
BTIG, LLC as an agent that the Company has engaged in connection with the transactions contemplated by this Agreement. The Company was
not and is not an “ineligible issuer” as defined in Rule 405 under the Securities Act..”
3. Section 6(ll)
of the Sales Agreement is hereby deleted in its entirety and replaced with the following:
“Market
Capitalization. As of the close of trading on the Exchange on August 14, 2023, the aggregate market value of the outstanding voting
and non-voting common equity (as defined in Rule 405) of the Company held by persons other than affiliates of the Company (pursuant
to Rule 144 of the Securities Act, those that directly, or indirectly through one or more intermediaries, control, or are controlled
by, or are under common control with, the Company) (the “Non-Affiliate Shares”), was approximately $96,376,755
(calculated by multiplying (x) the price at which the common equity of the Company was last sold on the Exchange on August 14, 2023
by (y) the number of Non-Affiliate Shares outstanding on August 14, 2023). The Company is not a shell company (as defined in Rule
405 under the Securities Act) and has not been a shell company for at least 12 calendar months previously and if it has been a shell company
at any time previously, has filed current “Form 10 information” (as defined in Instruction 4 to General Instruction I.B.6.
of Form S-3) with the Commission at least 12 calendar months previously reflecting its status as an entity that is not a shell company.”
4. Section 13
of the Sales Agreement is hereby deleted in its entirety and replaced with the following:
“All notices or other communications required or permitted to
be given by any party to any other party pursuant to the terms of this Agreement shall be in writing, unless otherwise specified, and
if sent to BTIG, shall be delivered to:
BTIG, LLC
65 E 55th Street
New York, NY 10022
Attention: Equity Capital Markets
Email: BTIGUSATMTrading@btig.com
with copies (which shall not
constitute notice) to:
BTIG, LLC
600 Montgomery Street, 6th Floor
San Francisco, CA 94111
Attention: General Counsel and Chief Compliance Officer
Email: BTIGcompliance@btig.com
legal@btig.com
and:
Lowenstein Sandler LLP
1251 Avenue of the Americas
New York, NY 10020
Telephone: (212) 262-6700
Facsimile: (212) 262-7402
Attention: Steven M. Skolnick
Email: sskolnick@lowenstein.com
and if to the Company, shall be delivered
to:
INmune Bio Inc.
225 NE Mizner Blvd., Suite 640
Boca Raton, FL 33432
Attention: David J. Moss, CFO
Email: dmoss@inmunebio.com
with a copy (which shall not constitute notice)
to:
Sichenzia Ross Ference LLP
1185 Avenue of the Americas, 31st Floor
New York, NY 10036
Attention: Marc Ross, Esq.
Email: mross@srf.law
Each party may change
such address for notices by sending to the other party to this Agreement written notice of a new address for such purpose. Each such notice
or other communication shall be deemed given (i) when delivered personally or by verifiable facsimile transmission (with an original to
follow) on or before 4:30 p.m., New York City time, on a Business Day or, if such day is not a Business Day, on the next succeeding Business
Day, (ii) on the next Business Day after timely delivery to a nationally-recognized overnight courier and (iii) on the Business Day actually
received if deposited in the U.S. mail (certified or registered mail, return receipt requested, postage prepaid). For purposes of this
Agreement, “Business Day” shall mean any day on which the Exchange and commercial banks in the City of New York
are open for business.
An electronic communication
(“Electronic Notice”) shall be deemed written notice for purposes of this Section 13 if sent to the electronic
mail address specified by the receiving party under separate cover. Electronic Notice shall be deemed received at the time the party sending
Electronic Notice receives confirmation of receipt by the receiving party (other than pursuant to auto-reply). Any party receiving Electronic
Notice may request and shall be entitled to receive the notice on paper, in a nonelectronic form (“Nonelectronic Notice”)
which shall be sent to the requesting party within ten (10) days of receipt of the written request for Nonelectronic Notice.”
5. Schedule
1 is hereby amended by adding the words “as amended on August 16, 2023” immediately after “March 10, 2021”
in such Schedule.
6. The first sentence
of the Form of Officer’s Certificate attached as Exhibit 7(m) is hereby amended by adding the words “as amended on
August 16, 2023” immediately after “March 10, 2021” in such sentence.
7. The first sentence
of the Form of Certificate of Chief Scientific Officer attached as Exhibit 7(p) is hereby amended by adding the words “as
amended on August 16, 2023” immediately after “March 10, 2021” in such sentence.
B. No Other Amendments.
Except as amended as set forth in Part A above, all of the terms and provisions of the Sales Agreement shall continue in full force
and effect and shall not be in any way changed, modified or superseded by this Amendment.
C. Counterparts. This
Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument. Delivery of an executed Amendment by one party to the other may be made by facsimile or email transmission.
D. Governing Law. This
Amendment shall be governed by, and construed in accordance with, the internal laws of the State of New York without regard to the principles
of conflicts of laws.
[Remainder of page intentionally left blank.]
If the foregoing correctly
sets forth the understanding between us, please so indicate in the space provided below for that purpose.
| |
Very truly yours, |
| |
|
| |
INMUNE BIO INC. |
| |
|
| |
By: |
/s/ David Moss |
| |
Name: |
David Moss |
| |
Title: |
Chief Financial Officer |
| |
|
| |
ACCEPTED as of the date first-above written: |
| |
|
| |
BTIG, LLC |
| |
|
| |
By: |
/s/ KC Stone |
| |
Name: |
KC Stone |
| |
Title: |
Managing Director |
[Signature Page to Amendment No. 1 to Sales
Agreement]
5
Exhibit 5.1
August
16, 2023
INmune Bio Inc.
225 ne Mizner Blvd., Suite 640
Boca Raton, Florida 33432
Re: Securities Registered
under Registration Statement on Form S-3 (File No. 333-254221)
Ladies and Gentlemen:
You have requested our
opinion with respect to certain matters in connection with the proposed offer and sale by INmune Bio Inc., a Nevada corporation (the “Company”),
of up to an aggregate of $28,701,161.61 INmune Bio, Inc. of shares of the Company’s common stock (the “Placement Shares”),
pursuant to a Registration Statement on Form S-3 (File No. 333-254221) (the “Registration Statement”), which was originally
filed under the Securities Act of 1933, as amended (the “Securities Act”) with the Securities and Exchange Commission (“SEC”)
on March 12, 2021 and declared effective by the SEC on May 5, 2021, the base prospectus contained in the Registration Statement (the “Base
Prospectus”), and the prospectus supplement relating to the proposed offer and sale of the Placement Shares filed with the SEC on
August 16, 2023 pursuant to Rule 424(b) of the rules and regulations under the Securities Act (the “Prospectus Supplement”,
and together with the Base Prospectus, the “Prospectus”). We understand that the Placement Shares are proposed to be offered
and sold by the Company through BTIG, LLC. (the “Agent”) pursuant to an At-the-Market Sales Agreement by and between the Company
and the Agent (the “At-the-Market Sales Agreement”) as amended by Amendment No.1 to the At-the-Market Sales Agreement.
In connection with the
preparation of this opinion, we have examined such documents and considered such questions of law as we have deemed necessary or appropriate.
We have assumed the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted
to us as copies thereof and the genuineness of all signatures. As to questions of fact material to our opinions, we have relied upon the
certificates of certain officers of the Company without independent investigation or verification.
Further, in connection
with our opinions expressed below, we have assumed that, (i) at or prior to the time of the delivery of any of the Placement Shares,
there will not have occurred any change in the law or the facts affecting the validity of the Placement Shares, (ii) at the time
of the offer, issuance and sale of any Placement Shares, no stop order suspending the Registration Statement’s effectiveness will
have been issued and remain in effect, (iii) no future amendments will be made to the company’s Articles of Incorporation that
would be in conflict with or inconsistent with the Company’s right and ability to issue the Placement Shares, (iv) at the time
of each offer, issuance and sale of any Placement Shares, the Company will have a sufficient number of authorized and unissued and unreserved
shares of the applicable class or series of its capital stock included in (or purchasable upon exercise or conversion of) the Placement
Shares so issued and sold (after taking into account all other outstanding securities of the Company which may require the Company to
issue shares of such applicable class or series) to be able to issue all such shares, and (v) all purchasers of the Placement Shares
will timely pay in full to the Company all amounts they have agreed to pay to purchase such Placement Shares, as approved by the Board
of Directors of the Company or a duly authorized committee thereof, and that the purchase price of any Placement Shares will not be less
than the par value thereof.
1185 Avenue of the Americas | 31st Floor
| New York, NY | 10036
T (212) 930 9700 | F (212) 930 9725 | WWW.SRF.LAW
We express no opinion
regarding the effectiveness of any waiver or stay, extension or of unknown future rights. Further, we express no opinion regarding the
effect of provisions relating to indemnification, exculpation or contribution to the extent such provisions may be held unenforceable
as contrary to federal or state securities laws or public policy.
With respect to our opinion
expressed below, we have assumed that, upon the issuance of any of the Placement Shares, the total number of shares of Common Stock issued
and outstanding and reserved for future issuance will not exceed the total number of shares of Common Stock that the Company is then authorized
to issue under its Articles of Incorporation as then in effect.
Based on the foregoing,
we are of the opinion that the Placement Shares have been duly authorized and, when issued and sold in the manner described in the Registration
Statement, the Prospectus and the At-the-Market Sales Agreement, as amended by Amendment No.1 to the At-the-market Sales Agreement, will
be validly issued, fully paid and non-assessable.
We are members of the
bar of the State of New York. We express no opinion as to the laws of any jurisdiction other than the laws of the State of New York, and
the federal laws of the United States of America. Insofar as the matters covered by this opinion may be governed by the laws of
other states we have assumed that such laws are identical in all respects to the laws of the State of New York.
We hereby consent to the
use of this opinion as Exhibit 5.1 to the Company’s Current Report on Form 8-K filed with the SEC on the date hereof, which is incorporated
by reference into the Registration Statement, and further consent to the reference to us in the Registration Statement and any amendments
thereto. In giving such consent, we do not hereby admit that we are within the category of persons whose consent is required under Section
7 of the Securities Act or the rules and regulations thereunder.
This opinion is intended
solely for use in connection with the offer and sale of the Placement Shares pursuant to the Registration Statement and is not to be relied
upon for any other purpose or delivered to or relied upon by any other person without our prior written consent. This opinion is rendered
as of the date hereof and based solely on our understanding of facts in existence as of such date after the examination described in this
opinion. We assume no obligation to advise you of any fact, circumstance, event or change in the law or the facts that may hereafter be
brought to our attention whether or not such occurrence would affect or modify the opinions expressed herein.
| |
Very truly yours, |
| |
|
| |
/s/ Sichenzia Ross Ference LLP |
| |
|
| |
SICHENZIA ROSS FERENCE LLP |
1185 Avenue of the Americas | 31st Floor
| New York, NY | 10036
T (212) 930 9700 | F (212) 930 9725 | WWW.SRF.LAW
v3.23.2
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Mar 2024 to Apr 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Apr 2023 to Apr 2024
